

## LOYALTY OPTIONS UPDATE

---

The Company is pleased to advise that the prospectus for the issue of loyalty options is expected to be lodged with ASIC and released to ASX on 1 March 2018. The anticipated record date to establish entitlements to loyalty options is 7 March 2018 and the anticipated expiry date for the loyalty options is 4 December 2018.

The Company confirms, to avoid any doubt, that the loyalty options will be issued to eligible holders of the Company's ordinary shares as at the record date, whether the shares were acquired before, in or after the IPO. Holders as at the record date are not required to have acquired their shares under the IPO, nor to have held the shares continuously since the IPO.

The Company has also received confirmation from ASX that the loyalty options to be received by holders of restricted (escrowed) shares will be freely tradable.

Eligible shareholders will be holders as at the record date whose address in the Company's shareholder register is in Australia or New Zealand. The Company intends to apply for the listing of the loyalty options, subject to satisfaction of the requirements of the ASX Listing Rules applying to quotation of a secondary class of securities.

Further details will be contained in the loyalty options prospectus. All dates will be confirmed in the formal timetable which will be contained in the prospectus. The prospectus for loyalty options will be sent to all eligible shareholders after the record date, however eligible shareholders will not need to return an application form or do anything else to receive their loyalty options.

The Company will make further announcements, including announcing to ASX when the loyalty options have been issued and holding statements dispatched.

### For further information, please contact:

Bio-Gene Technology Limited:

Richard Jagger

Chief Executive Officer

P: 03 9628 4178

E: [bgt.info@bio-gene.com.au](mailto:bgt.info@bio-gene.com.au)

Roger McPherson

CFO & Company Secretary

P: 03 9628 4178

E: [bgt.info@bio-gene.com.au](mailto:bgt.info@bio-gene.com.au)

Media/investor relations:

Matthew Wright

NWR Communications

P: 0451 896 420

E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

### About Bio-Gene Technology Limited

Bio-Gene is an Australian AgTech development company enabling the next generation of novel insecticides to address the global problems of insecticide resistance and toxicity. Its novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Beta-triketone compounds have demonstrated insecticidal activity (e.g. kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across animal health and crop protection, as well as in public health, and in consumer applications.

The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions.

**Bio-Gene Technology Limited**

ABN: 32 071 735 950

Suite 1, Level 6, 50 Queen St, Melbourne, VIC 3000